Awakn Life Sciences Corp. AWKN has officially announced the launch of a research program studying the use of ketamine in substance abuse disorder and behavioral addictions.
In a recent interview with Benzinga, Anthony Tennyson, CEO of the UK-based company, explained how Awakn’s research into ketamine will allow it to improve protocols for delivering treatment at its own clinics.
Research will be led by Professor Celia Morgan from the University of Exeter in the UK.
The new program will consist of a late-stage clinical trial focused on alcohol use disorder and a mechanistic study focused on gambling addiction as well as intellectual property development activities.
Morgan said patients with alcohol use disorder these days are poorly served by existing treatments that are known to have very high relapse rates.
“Ketamine-assisted psychotherapy has the potential to deliver a significant improvement on existing therapeutic strategies, and at Awakn we aim to prove this via a rigorous set of planned studies and trials,” Morgan added.
Ketamine, today a legally prescribed anesthetic drug, is widely used in an off-label capacity for the treatment of a host of mental health conditions, although clinical research leading to standardized protocols has been scarce.
Photo by Bianca Berg on Unsplash
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.